Chronic pain is a complex disorder with multiple etiologies for which the pathologic mechanisms are still largely unknown, making effective treatment a difficult clinical task.
INTRODUCTION
Acute and chronic pain affects millions of Americans. Each year, 25 million people will experience an acute pain event (resolving in \2 weeks), whereas 50 million live with chronic pain [1] ; furthermore, as the American population ages, the incidence of chronic pain is expected to only increase. For instance, up to 10% of all American adults report chronic pain; however, this increases to 60% in those older than 65 [2] . Missed work and increased healthcare costs attributed to chronic pain conditions have been estimated to exceed 100 billion dollars annually [3] . Chronic pain manifests with both behavioral and physical components, and it is known that genetics, environment, and diet all impact the generation of pain and analgesic responsiveness. Most often, the clinical presentation and treatment of chronic pain patients is extremely complex, and simple solutions or single modalilty therapy offer limited benefit. Nevertheless, a general lack of acceptance of this axiom may explain why current chronic pain treatments are not more efficacious. Clearly, there is a tremendous need to better understand chronic pain mechanisms and to create novel and effective multimodal treatment options for clinicians and patients. Topical analgesics (TAs) have been used for centuries in the traditional medical approaches of China and other countries. For example,
writings from before 600 BC on the treatment of headache list a plethora of topical options, including botanicals and animal-derived products [4] . The first formal report of the pain-reducing properties of topical capsaicin in the West appeared in 1850 as a recommendation to use an alcoholic hot pepper extract for burning or itching extremities [5] . Unfortunately, despite the long history of TA use, their well-documented benefits, and their current use in traditional types of medicine, TAs are underutilized.
Neuropathic pain is a chronic condition of the somatosensory nervous system that severely impairs the health and quality of life of 5-10% of humans, with a total United States economic impact estimated at more than $600 billion annually [6] . Neuropathic pain, by definition, originates from neural pathology and dysfunctions in the peripheral and/or central nervous system (CNS) resulting in high levels of cortical activity among regions known to influence pain perception. Many types of neuropathic pain originate within peripheral tissues, such as skin, ostensibly driven by hyperexcitability of primary afferents. As such, topical approaches may be effective in alleviating neuropathic pain at the source, and this concept underlies most of the evidence for the function of TAs. TAs can target regional pain through affected skin, where they interfere with the peripheral nociceptive mechanisms directly, by modulating the activity of small nerve fibers, and/or indirectly, via non-neuron interactions (e.g., skin resident cells, keratinocytes, and monocyte-derived infiltrated immune cells). In addition, TAs may reach deeper tissues and act on underlying somatic peripheral nerves.
TAs can be delivered as liquids, ointments, gels, powders, creams, semisolids, emulsions, patches, foams, or aerosols. They are mixed with adjuvants, which enhance viscosity and permeation, and emollients and preservatives.
Effective TAs are water soluble and lipophilic, with the delivery goals of reducing drug concentration, increasing local tissue absorption, and holding the drug at the application site. Moreover, TAs avoid standard issues that follow the oral ingestion of medications, such as gastric ulceration, firstpass hepatic metabolism, and problems associated with variable serum concentrations.
However, there is distinct individual variation in both skin physiology and metabolism that might affect the absorption and drug distribution of TAs. Ultrasound, electricity, and lasers have all been used to facilitate the permeability and delivery of various topical preparations [7, 8] . This article will not discuss either these delivery approaches or the use of TAs for venipuncture in pediatrics. In this first part of this two-part article on TAs, we discuss basic skin innervation and immunocytochemical characteristics under both normal and neuropathic conditions. Insights into skin function and potential therapies are derived from a discussion of research models using topical capsaicin. We also review other pharmacologic formulations and delivery systems. This review article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
MORPHOLOGY, INNERVATION, AND IMMUNOCYTOCHEMICAL CHARACTERISTICS OF SKIN
The skin is a protective barrier designed to absorb daily physical abuse and environmental extremes. Skin is also the largest sensory organ, providing an essential interface between an organism and external stimuli. However, its exposed location and extreme complexity predisposes the skin, and its (Fig. 1f) Meissner corpuscles and piloneural complexes were present, but were profoundly disorganized (Fig. 1g, h ) [17, 18] . These data suggest that the numbness might be due to abnormal activity from this innervation rather than a loss of innervation, and aberrant piloneural complexes observed in the patients with CRPS may contribute to the profound mechanical allodynia caused by slight movements of hairs.
Pathologies among Vascular Innervation
Afferents containing CGRP/SP have been implicated in an axon-reflex-mediated increase in vascular dilation and permeability of capillaries and precapillary arterioles in the upper dermis as well as in pain sensation in response to intense heat. However, relatively little research has been directed toward the extensive, dense, sensory innervation to the arterioles and arteriole-venule shunts (AVS) in the deeper dermis [16, 40, 41] . Nearly all of the attention to the innervation of these deeper vessels has been focused on the sympathetic innervation, which is primarily noradrenergic, with a recently identified cholinergic contingent [16] . The sensory innervation of deeper vessels consists of several types of C and Ad fibers, most of which also express CGRP and SP (Fig. 1c, i) [49] . However, if one looks closely at the studies, the differences appear attributable to the different drug doses and dose scheduling [50] [51] [52] . Table 2 shows properties of different classes of topical drugs studied using capsaicin models. A sodium channel antagonist (4030W92) was shown to be ineffective in an intradermal capsaicin model and had negative effect in a multicenter trial on neuropathic pain with mappable allodynia [53, 54] . Cannabis was studied in this model, but the results showed that a low dose was no different from placebo, and a medium dose reduced, whereas a high dose increased, pain [55] .
The identification of the nature of the underlying pathologies and how they may differ from disease to disease and patient to patient pose a major challenge to the development of more effective strategies and therapeutics for treating neuropathic pain originating from the skin and its innervation. Table 2 Studies of topical compounds using capsaicin models This study was done in healthy subjects without neuropathic or postoperative pain
FORMULATIONS AND APPLICATIONS
When considering the use of a TA, the risk and severity of adverse effects and drug-drug interactions are less than for the same analgesic administered systemically [56] . Obviously, this is clinically relevant when managing a patient who has been prescribed multiple concurrent systemic medications. [59] . Considering using TAs that have more than one mechanism of action might be more efficacious than use of a single TA; for example, the antinociceptive effects of topical morphine may be enhanced by a topical cannabinoid as suggested in a rat study [60] . This is intuitive for those who treat chronic pain and could be considered ''rational topical polypharmacy''.
CONCLUSION
TAs provide a therapeutic option with decreased side effects and decreased drug-drug interactions for patients with neuropathic and other disabling chronic pain syndromes. The range of potential targets that can be used as TAs is expanding. The pharmaceutical industry is taking interest in developing some of these options into marketable products, all of which should help patients with pain. In Part Two of this article, we discuss specific drugs that can be used as TAs as well as the potential to determine through physical examination who would benefit most from specific agents. 
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